Shopping Cart 0
Cart Subtotal
USD 0

Orion Corp (ORNBV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Orion Corp (Orion) is a developer of pharmaceuticals and diagnostic tests. The company develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients (APIs) and diagnostic tests. It focuses on developing pharmaceutical products for central nervous system disorders, cancer and respiratory. Orion's client base consists of healthcare service providers and professionals, such as doctors, pharmacies, veterinarians, hospitals, healthcare centers, clinics and laboratories. The company sells its products in European markets through own human pharmaceuticals sales organization; and in international markets through several collaboration partners. It operates all manufacturing plants and most of its R&D facilities in Finland. Orion is headquartered in Espoo, Finland.

Orion Corp (ORNBV)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Orion Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Orion Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Orion Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Orion Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Orion Corp, Medical Devices Deals, 2012 to YTD 2018 10

Orion Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Orion Corp, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Orion and Amgen Enter into Marketing Agreement 12

Orion to Partner with Wisconsin Technology Innovation Initiative 13

Immunscape Enters into Research Collaboration with Orion 14

Orion Enters into Co-Marketing Agreement with A. Menarini Industrie Farmaceutiche Riunite 15

Orion Enters into Agreement with Asahi Kasei Pharma 16

Orion Enters into Co-Development Agreement with Helsinki University 17

Orion Enters into Agreement with Bayer for Prostate Cancer Treatment 18

Jubilant Biosys Enters Into Drug Discovery Agreement With Orion 19

Orion Enters Into R&D Agreement With Gedeon Richter For Cognitive Disorders 20

Licensing Agreements 21

Aurigene and Orion Enter into Research and Option Agreement for Epigenetics Program 21

Orion Enters Into Licensing Agreement With Janssen Pharma 22

Orion Enters into License Agreement with Phyxius Pharma 23

A. Menarini Industrie Farmaceutiche Riunite Enters into Licensing Agreement with Orion 24

Orion And Hospira Extend Licensing Agreement For Precedex 25

Mylan Enters Into Licensing Agreement With Orion for Stalevo 26

Orion Enters Into Licensing Agreement With ProStrakan For Fareston 27

Debt Offering 28

Orion Announces Public Offering Of Bond Due 2019 For USD 193 Million 28

Orion Corp-Key Competitors 29

Orion Corp-Key Employees 30

Orion Corp-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Recent Developments 33

Financial Announcements 33

Jul 18, 2018: Orion: Half-year financial report January-June 2018 33

Feb 07, 2018: Orion Group Financial Statement Release for 2017 46

Jul 19, 2017: Orion Group Half-Year Financial Report January-June 2017 53

Apr 26, 2017: Orion Group Interim Report January-March 2017 62

Feb 08, 2017: Orion Group Financial Statement Release for 2016 63

Corporate Communications 66

Sep 19, 2018: Changes in responsibility areas of the Orion Group executive management board 66

Feb 13, 2017: Change in Orion Group Executive Management Board as of 21 February 2017 67

Jan 27, 2017: Reijo Salonen, Senior Vice President, Pharmaceutical R&D, is CTO of the Year 2017 68

Government and Public Interest 69

Nov 01, 2018: Orion Research Foundation grants million euros for research in 2019 69

Feb 10, 2017: Orion Research Foundation grants EUR 1 million for research 71

Product News 72

12/20/2017: Alpha 2 agonizing sedative agent Pressedex Intravenous solution 200 g Pfizer applies for adaptation to children 72

06/29/2018: CHMP announces recommendations on extensions of therapeutic indication for Dexdor 73

04/05/2017: Tenax Therapeutics Announces Review of Strategic Alternatives and Business Update 74

03/19/2017: Use of levosimendan with heart-lung machine fails to improve outcomes 75

Clinical Trials 76

Sep 01, 2017: Bayer to Present Abstract on Darolutamide at ESMO 2017 Congress 76

May 16, 2017: Tenax Meets with FDA to Discuss Positive Mortality Data and Potential Levosimendan NDA Submission 77

Jan 31, 2017: Tenax Therapeutics Announces Top-Line Results From Phase 3 LEVO-CTS Trial in Cardiac Surgery 78

Other Significant Developments 79

Sep 17, 2018: Creation of novel medicines and better patient care for the future in an ecosystem 79

Jun 14, 2018: Fermion's new plant operational in Hanko-nearly 100% of production is exported 80

Feb 28, 2018: Orion's Statutory Co-operation Negotiations Completed 81

Jan 04, 2018: Orion to renew operating model of its laboratories 82

Appendix 83

Methodology 83

About GlobalData 83

Contact Us 83

Disclaimer 83


List Of Figure

List of Figures

Orion Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Orion Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Orion Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Orion Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Orion Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Orion Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Orion Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Orion Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Orion Corp, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Orion Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Orion Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Orion Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Orion Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Orion Corp, Deals By Therapy Area, 2012 to YTD 2018 9

Orion Corp, Medical Devices Deals, 2012 to YTD 2018 10

Orion Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Orion and Amgen Enter into Marketing Agreement 12

Orion to Partner with Wisconsin Technology Innovation Initiative 13

Immunscape Enters into Research Collaboration with Orion 14

Orion Enters into Co-Marketing Agreement with A. Menarini Industrie Farmaceutiche Riunite 15

Orion Enters into Agreement with Asahi Kasei Pharma 16

Orion Enters into Co-Development Agreement with Helsinki University 17

Orion Enters into Agreement with Bayer for Prostate Cancer Treatment 18

Jubilant Biosys Enters Into Drug Discovery Agreement With Orion 19

Orion Enters Into R&D Agreement With Gedeon Richter For Cognitive Disorders 20

Aurigene and Orion Enter into Research and Option Agreement for Epigenetics Program 21

Orion Enters Into Licensing Agreement With Janssen Pharma 22

Orion Enters into License Agreement with Phyxius Pharma 23

A. Menarini Industrie Farmaceutiche Riunite Enters into Licensing Agreement with Orion 24

Orion And Hospira Extend Licensing Agreement For Precedex 25

Mylan Enters Into Licensing Agreement With Orion for Stalevo 26

Orion Enters Into Licensing Agreement With ProStrakan For Fareston 27

Orion Announces Public Offering Of Bond Due 2019 For USD 193 Million 28

Orion Corp, Key Competitors 29

Orion Corp, Key Employees 30

Orion Corp, Subsidiaries 31

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Orion Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Orion Corp (Orion) is a developer of pharmaceuticals and diagnostic tests. The company develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients (APIs) and diagnostic tests. It focuses on developing pharmaceutical products for central nervous system disorders, cancer and respiratory. Orion's client base consists of healthcare service providers and professionals, such as doctors, pharmacies, veterinarians, hospitals, healthcare centers, clinics and laboratories. The company sells its products in European markets through own human pharmaceuticals sales organization; and in international markets through several collaboration partners. It operates all manufacturing plants and most of its R&D facilities in Finland. Orion is headquartered in Espoo, Finland.

Orion Corp (ORNBV)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Orion Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Orion Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Orion Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Orion Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Orion Corp, Medical Devices Deals, 2012 to YTD 2018 10

Orion Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Orion Corp, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Orion and Amgen Enter into Marketing Agreement 12

Orion to Partner with Wisconsin Technology Innovation Initiative 13

Immunscape Enters into Research Collaboration with Orion 14

Orion Enters into Co-Marketing Agreement with A. Menarini Industrie Farmaceutiche Riunite 15

Orion Enters into Agreement with Asahi Kasei Pharma 16

Orion Enters into Co-Development Agreement with Helsinki University 17

Orion Enters into Agreement with Bayer for Prostate Cancer Treatment 18

Jubilant Biosys Enters Into Drug Discovery Agreement With Orion 19

Orion Enters Into R&D Agreement With Gedeon Richter For Cognitive Disorders 20

Licensing Agreements 21

Aurigene and Orion Enter into Research and Option Agreement for Epigenetics Program 21

Orion Enters Into Licensing Agreement With Janssen Pharma 22

Orion Enters into License Agreement with Phyxius Pharma 23

A. Menarini Industrie Farmaceutiche Riunite Enters into Licensing Agreement with Orion 24

Orion And Hospira Extend Licensing Agreement For Precedex 25

Mylan Enters Into Licensing Agreement With Orion for Stalevo 26

Orion Enters Into Licensing Agreement With ProStrakan For Fareston 27

Debt Offering 28

Orion Announces Public Offering Of Bond Due 2019 For USD 193 Million 28

Orion Corp-Key Competitors 29

Orion Corp-Key Employees 30

Orion Corp-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Recent Developments 33

Financial Announcements 33

Jul 18, 2018: Orion: Half-year financial report January-June 2018 33

Feb 07, 2018: Orion Group Financial Statement Release for 2017 46

Jul 19, 2017: Orion Group Half-Year Financial Report January-June 2017 53

Apr 26, 2017: Orion Group Interim Report January-March 2017 62

Feb 08, 2017: Orion Group Financial Statement Release for 2016 63

Corporate Communications 66

Sep 19, 2018: Changes in responsibility areas of the Orion Group executive management board 66

Feb 13, 2017: Change in Orion Group Executive Management Board as of 21 February 2017 67

Jan 27, 2017: Reijo Salonen, Senior Vice President, Pharmaceutical R&D, is CTO of the Year 2017 68

Government and Public Interest 69

Nov 01, 2018: Orion Research Foundation grants million euros for research in 2019 69

Feb 10, 2017: Orion Research Foundation grants EUR 1 million for research 71

Product News 72

12/20/2017: Alpha 2 agonizing sedative agent Pressedex Intravenous solution 200 g Pfizer applies for adaptation to children 72

06/29/2018: CHMP announces recommendations on extensions of therapeutic indication for Dexdor 73

04/05/2017: Tenax Therapeutics Announces Review of Strategic Alternatives and Business Update 74

03/19/2017: Use of levosimendan with heart-lung machine fails to improve outcomes 75

Clinical Trials 76

Sep 01, 2017: Bayer to Present Abstract on Darolutamide at ESMO 2017 Congress 76

May 16, 2017: Tenax Meets with FDA to Discuss Positive Mortality Data and Potential Levosimendan NDA Submission 77

Jan 31, 2017: Tenax Therapeutics Announces Top-Line Results From Phase 3 LEVO-CTS Trial in Cardiac Surgery 78

Other Significant Developments 79

Sep 17, 2018: Creation of novel medicines and better patient care for the future in an ecosystem 79

Jun 14, 2018: Fermion's new plant operational in Hanko-nearly 100% of production is exported 80

Feb 28, 2018: Orion's Statutory Co-operation Negotiations Completed 81

Jan 04, 2018: Orion to renew operating model of its laboratories 82

Appendix 83

Methodology 83

About GlobalData 83

Contact Us 83

Disclaimer 83


List Of Figure

List of Figures

Orion Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Orion Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Orion Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Orion Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Orion Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Orion Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Orion Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Orion Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Orion Corp, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Orion Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Orion Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Orion Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Orion Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Orion Corp, Deals By Therapy Area, 2012 to YTD 2018 9

Orion Corp, Medical Devices Deals, 2012 to YTD 2018 10

Orion Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Orion and Amgen Enter into Marketing Agreement 12

Orion to Partner with Wisconsin Technology Innovation Initiative 13

Immunscape Enters into Research Collaboration with Orion 14

Orion Enters into Co-Marketing Agreement with A. Menarini Industrie Farmaceutiche Riunite 15

Orion Enters into Agreement with Asahi Kasei Pharma 16

Orion Enters into Co-Development Agreement with Helsinki University 17

Orion Enters into Agreement with Bayer for Prostate Cancer Treatment 18

Jubilant Biosys Enters Into Drug Discovery Agreement With Orion 19

Orion Enters Into R&D Agreement With Gedeon Richter For Cognitive Disorders 20

Aurigene and Orion Enter into Research and Option Agreement for Epigenetics Program 21

Orion Enters Into Licensing Agreement With Janssen Pharma 22

Orion Enters into License Agreement with Phyxius Pharma 23

A. Menarini Industrie Farmaceutiche Riunite Enters into Licensing Agreement with Orion 24

Orion And Hospira Extend Licensing Agreement For Precedex 25

Mylan Enters Into Licensing Agreement With Orion for Stalevo 26

Orion Enters Into Licensing Agreement With ProStrakan For Fareston 27

Orion Announces Public Offering Of Bond Due 2019 For USD 193 Million 28

Orion Corp, Key Competitors 29

Orion Corp, Key Employees 30

Orion Corp, Subsidiaries 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Orion Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.